Urology

The FDA has approved a drug for the treatment of patients with with locally advanced or metastatic urothelial carcinoma.

The FDA granted accelerated approval for a new treatment for patients with locally advanced or metastatic urothelial carcinoma.

The FDA has expanded the use of Opdivo (nivolumab) for the treatment of patients with urothelial carcinoma, the most common form of bladder cancer.